Genmab A/S Sponsored ADR $GMAB Stock: Pictet Asset Management Holding SA Raises Stake

Pictet Asset Management Holding SA raised its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 8.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 1,150,854 shares of the company’s stock after purchasing an additional 84,927 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Genmab A/S were worth $41,044,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Parallel Advisors LLC boosted its position in Genmab A/S by 3.0% during the 3rd quarter. Parallel Advisors LLC now owns 6,274 shares of the company’s stock valued at $224,000 after buying an additional 183 shares during the period. Kestra Advisory Services LLC lifted its holdings in shares of Genmab A/S by 19.1% during the third quarter. Kestra Advisory Services LLC now owns 14,315 shares of the company’s stock valued at $511,000 after purchasing an additional 2,299 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in Genmab A/S by 5.5% during the third quarter. Commonwealth Equity Services LLC now owns 29,217 shares of the company’s stock valued at $1,042,000 after purchasing an additional 1,526 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Genmab A/S in the third quarter worth $177,000. Finally, Vise Technologies Inc. increased its position in shares of Genmab A/S by 41.6% during the 3rd quarter. Vise Technologies Inc. now owns 23,186 shares of the company’s stock valued at $827,000 after purchasing an additional 6,809 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GMAB. New Street Research set a $43.00 target price on Genmab A/S in a report on Wednesday, July 22nd. Weiss Ratings raised shares of Genmab A/S from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. HC Wainwright boosted their price target on shares of Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Guggenheim lifted their target price on Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Finally, Truist Financial reissued a “buy” rating and issued a $67.00 price objective (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Buy” and a consensus price target of $53.61.

Genmab A/S Trading Down 3.1%

NASDAQ:GMAB opened at $54.07 on Wednesday. The firm has a 50-day simple moving average of $40.05 and a 200-day simple moving average of $31.33. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.43 and a current ratio of 2.45. The firm has a market cap of $33.74 billion, a P/E ratio of 42.92, a P/E/G ratio of 2.25 and a beta of 0.73. Genmab A/S Sponsored ADR has a one year low of $23.62 and a one year high of $59.97.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.20. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. Equities analysts anticipate that Genmab A/S Sponsored ADR will post 1.28 EPS for the current fiscal year.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $70 price target, above the share price in the supplied market data. MarketBeat report
• Neutral Sentiment: Genmab disclosed an increase of 164,828 shares following employee warrant exercises. The issuance creates some dilution, though the announcement does not indicate its likely financial impact. Capital increase announcement
• Neutral Sentiment: Genmab reported managerial and associated-person transactions, but the supplied notice provides no transaction details to indicate whether they were purchases or sales. Managerial transaction announcement
• Negative Sentiment: HC Wainwright cut several quarterly and annual EPS forecasts, including its FY2027 estimate to $1.60 from $2.15. The firm still rates the stock Buy, but the downward revisions could pressure sentiment.
• Negative Sentiment: Reported short interest rose 46.4% from mid-October to 9.66 million shares as of October 30, suggesting increased bearish positioning. It was still about 1.6% of shares, with a 1.2-day short-interest ratio.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.